Drug-Drug:
- May ↑ levels of CYP2C8 substrates, including dabrafenib, dasabuvir, enzalutamide, loperamide, montelukast, paclitaxel, pioglitazone, or selexipag; concurrent use with dasabuvir or selexipag contraindicated.
- May ↑ levels of OATP1B1 substrates, including atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, repaglinide, rifampin, rosuvastatin, simvastatin, and valsartan; concurrent use with simvastatin or repaglinide is contraindicated; avoid concurrent use with other HMG-CoA reductase inhibitors.
- May ↑ levels and the risk of bleeding with warfarin.
- Concurrent use with colchicine may ↑ risk of rhabdomyolysis, especially in patients with renal dysfunction or older adults.
- May ↓ the effect of cyclosporine.
- Cholestyramine and colestipol may ↓ absorption; separate administration by
2 hr.